Calliditas Therapeutics announced that the United States Patent and Trademark Office has issued a patent for application no. 16/760,910 entitled “Use of NOX Inhibitors for Treatment of Cancer.” The patent covers a method of treating a solid tumor presenting resistance to PD-1 inhibitor immunotherapy by administering setanaxib in combination with a PD-1 inhibitor. The patent will have an expiration date in 2039. Calliditas has corresponding applications and patents in several additional territories around the world, including a pending patent application in Europe. Calliditas read out positive topline results of its Phase 2 head and neck cancer trial with setanaxib in May 2024. The analysis showed statistically significant improvements in progression-free survival, as well as in overall survival, with statistically significant changes in tumor biology consistent with the mechanism of action of setanaxib.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CALT:
- Calliditas Therapeutics’ Annual Meeting Highlights
- Calliditas Therapeutics downgraded to Hold from Buy at Pareto
- Calliditas Therapeutics downgraded to Hold from Buy at SEB Equities
- Wynn Resorts upgraded, PayPal initiated: Wall Street’s top analyst calls
- Calliditas Therapeutics downgraded to Neutral from Buy at Citi
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue